Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance

Completed · Phase 4 · Has a placebo group

Conditions studied: Expectancy Versus Pharmacotherapy Effect of Adderall

In brief

The purpose of this balanced-placebo design study is to pilot a larger study to further explore the current evidence that stimulant medications are not cognitive enhancers, despite this rampant belief in young adults. While the lack of cognitive enhancement from stimulant medication has been documented in prior research, this study is the first to utilize neuroimaging technology to examine brain regions activated during neurocognitive tasks when participants believe they have been administered stimulant medication or placebo.

Key facts

Study ID

NCT03530631

Run by

University of Alabama at Birmingham

People needed

4

Starts

2018-11-10

Expected to finish

2018-12-18

Last updated by the study team

2019-12-16

Who can join

Age: 18 and older, up to 24. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age (18-24)
• College student with at least average IQ
• Willingness to standardize caffeine intake to 100 mg on day of study

You may not qualify if…

• Attention Deficit/Hyperactivity Disorder (ADHD)
• First degree relative with ADHD
• Unwillingness to comply with caffeine specifications
• Regular use of Adderall
• Pregnant/breastfeeding
• History of substance use disorders
• Illicit stimulant use within the last year
• Contraindications to stimulants (i.e., tics, Tourette's, cardiac disease, hypertension)
• Uncontrolled medical illness
• Active contagious infection

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.